Ariad Pharmaceuticals Inc. said Monday it has agreed to be acquired by Takeda Pharmaceutical Co. Ltd. in a deal with an enterprise value of about $5.2 billion. Takeda will pay $24 in cash for each Ariad share owned for a premium of about 75% over Ariad's closing price on Jan. 6. The deal is expected to close by the end of February and is structured as an all cash tender offer. Ariad shares were halted for news pending, but have gained 158% in the last 12 months, while the S&P 500 has gained 18%.
Copyright © 2017 MarketWatch, Inc.